HTA bodies should take indirect costs in the scope to assess the cost/benefit of innovation.
After years of building expertise with Managed entry agreements, several challenges arose. In this blog we give you our opinion.
Quality of life (QoL) in our field of expertise is expressed in ‘utilities’. When performing health economic assessments, the delta utility between 2 clinical settings is measured. Be vigilant, though: the way the QoL is assessed in your study needs to be analysed carefully. In our blog we address some potential difficulties you may encounter.
Each health economic analysis starts with clinical data. But if your sample does not provide mature data, how can you use this data as reliably as possible?
To what level is it relevant to include costs in the analysis? For quite a few parameters, it is clear that they can have a decisive influence on your analysis, however, sometimes the effort you have to put into looking up data is not reflected in a meaningful impact on the results.
Before you introduce an innovation, you will collect data on a relatively limited scale, after which you will compare this to a similar dataset. But how can you make a good comparison and which information can you take into account?
Within healthcare, there is continuous innovation. New technologies are made available and (partly) replace existing resources or care. But how can you measure the financial value of innovation?
